Nervous System Under Siege, Longevity Gets Granular

Today’s market patterns show a sharpened focus on the nervous system’s role in health and disease, while longevity R&D segments populations by genetics and specific biological pathways.

In today's read: 1. Nervous system: the new central hub for biotech · 2. Longevity moves beyond broad strokes · 3. Access to care is breaking point for European health systems · 4. Big Pharma eyes muscle-sparing GLP-1 alternatives

1. Nervous system: the new central hub for biotech

Researchers are uncovering the nervous system's deep links to sleep, immunity, and chronic disease. Targeting brain proteins or mapping whole-body neural networks offers new drug and diagnostic pathways.

Watch for more investment in neuro-therapeutics beyond mental health. Startups focused on the brain-body axis, using imaging or 'molecular glues', are poised for breakout funding and clinical trials.

Evidence from today:

• New 'molecular glue' targets brain protein for nervous system diseases — Nature News — Researchers at Stanford University, led by Dr. Jared R. Schwalbe, published in Nature on a new 'molecular glue' drug, TRI-611. This compound targets ALK, anaplastic lymphoma kinase, a protein found in the brain, suggesting a novel pathway for neurodevelopmental and psychiatric disorders. It's a first step towards future therapies that could reshape how we treat these conditions.
• New imaging maps whole-body nervous system circuits — Nature News — Scientists developed a new brain-to-body imaging method, published in Nature, to visualize neuron activity across an entire organism in real-time. This reveals how different organs communicate directly with the brain, showing body-wide neural networks beyond the central nervous system. The technique has already identified novel connections between the brain and systems like the gut and adrenal glands.
• Brain inhibition linked to deeper, more synchronized sleep — Nature News — New research published in Nature found that specific long-range inhibitory neurons in the neocortex are key to promoting cortical synchrony and deeper sleep stages. Led by Dr. Antoine Adamantidis at the University of Bern, the study shows that activating these neurons can significantly enhance slow-wave sleep in mice.

2. Longevity moves beyond broad strokes

The longevity market is pivoting from general health to highly specific, targeted interventions. Genetic ancestry, epigenetics, and precise gene therapies are segmenting the 'aging' problem into manageable, addressable mechanisms.

Direct-to-consumer tests offering 'heart age' or genetic risk profiles will proliferate. Biotech firms with gene therapy platforms for specific conditions like sarcopenia or age-related blindness will attract serious capital and partnerships.

Evidence from today:

• Ancestry shapes inflammation and health risks in Mexican families — Nature News — New research in Nature found that genetic ancestry within Mexican families significantly influences chronic inflammation, BMI, and glucose levels, even when family members share an environment. This means two siblings could respond differently to the same diet based on their Indigenous American vs. European genetic split. It's a reminder that 'one-size-fits-all' is a fantasy, even within a single family.
• MyHeartCode uses epigenetics to map heart age — Longevity Technology — Genetic LifeSpan launched MyHeartCode, a new service using epigenetic data to predict heart aging, aiming to provide a more nuanced risk assessment than traditional cholesterol numbers. This direct-to-consumer test promises to give people a clearer picture of their cardiovascular health beyond a single biomarker.
• Genflow's gene therapy slows muscle loss in aged dogs — Longevity Technology — Genflow announced its SLAB (Sarcopenia and Longevity in Aged Beagles) clinical trial met its primary endpoint. The study, involving 24 beagle dogs over 10 years old, used gene therapy to target sarcopenia, showing it could preserve muscle mass in older animals. This points to new paths for human longevity research.
• MIT geneticist uses gene therapy to reverse age-related blindness — MIT Tech Review — Yuancheng (Ryan) Lu at Whitehead Institute developed a gene therapy to restore vision in age-related blindness by reversing cellular aging. The research, building on Nobel-winning Yamanaka factors, specifically targets eye cells, showing potential to regenerate tissues without causing tumors. This could change how we approach age-related degeneration.

3. Access to care is breaking point for European health systems

Budget cuts, staffing shortages, and policy shifts are limiting patient access to basic and specialized care, forcing doctors to strike or halt services. This hits vulnerable populations hardest and increases wait times.

Expect more patient frustration and political pressure to fix health policy in Germany and Spain. Private clinics or direct-pay models may gain traction as public systems fail, but health equity will suffer.

Evidence from today:

• German Anesthesiologists Warn Against Outpatient Care Budget Limits — Deutsches Ärzteblatt — The German Association of Anesthesiologists (BDA) is pushing to remove budget limits on outpatient anesthesia. They argue current caps could halt the shift to more outpatient surgeries mandated by a new law. This move could impact how easily patients access procedures outside of hospitals.
• German ENT doctors halt children's surgeries, citing costs — Deutsches Ärzteblatt — Nearly one-third of private ear, nose, and throat (ENT) doctors in Germany have stopped offering outpatient surgeries for children, according to a recent survey by the German Professional Association of ENT Doctors. Economic pressures are forcing clinics to abandon these procedures, leading to longer waiting times for kids needing critical interventions like tonsillectomies or ear tube insertions. This signals growing access issues for basic childhood health needs across the country.
• Spanish Doctors Strike Indefinitely Over Healthcare Policy — El Médico Interactivo — The State Confederation of Medical Unions (CESM) in Spain announced an indefinite national strike. Doctors want to pressure the government to negotiate better healthcare management and working conditions. This move will significantly impact patient care and public access to health services.

4. Big Pharma eyes muscle-sparing GLP-1 alternatives

The market recognizes GLP-1s lead to muscle loss. New drugs target fat cells directly or preserve lean muscle mass, shifting focus from overall weight to body composition. This improves metabolic health and reduces sarcopenia risk.

Expect a new wave of obesity drugs that prioritize muscle retention. Early movers like Moonwalk Biosciences, with Eli Lilly's backing, are shaping the next generation of weight management, likely creating tiered pricing for 'leaner' weight loss.

Evidence from today:

• Moonwalk Biosciences raises $70M for muscle-sparing obesity drug — Longevity Technology — Moonwalk Biosciences secured $70 million in Series B funding, co-led by Alpha Wave and YK Bioventures, with participation from Eli Lilly. The biotech firm plans to advance its lead obesity candidate, MW101, into human trials by late 2027. This drug is designed to address muscle loss often associated with current weight-loss medications like GLP-1s.
• Moonwalk Biosciences raised $70M for fat-targeted RNAi drug — Longevity Technology — Moonwalk Biosciences secured $70 million in Series B funding to develop an RNAi drug targeting fat cells without affecting appetite. The biotech aims to reduce fat mass while preserving lean muscle, with human trials starting in late 2027. This is for people who want to lose fat but not the muscle that comes with current weight-loss options.

Also moved today

• Immune Evasion in Pancreatic Cancer Tied to Serpin Protein — Nature News — A specific protein, serpin E2, helps pancreatic cancer cells evade the immune system, providing a new target for therapies.
• UK regulators review Biosplice's new knee pain drug — Longevity.Technology — UK regulators are reviewing Biosplice's new small-molecule injection, Lorecivivint, for knee osteoarthritis, which could be a first-in-class treatment.
• Sky Labs' CART Ring Monitors Blood Pressure 24/7 — Longevity.Technology — Sky Labs' CART ring offers 24/7 blood pressure monitoring, achieving an 80% data rate in AFib patients, shifting cardiovascular health from snapshots to continuous reads.
• Modified gut bacteria shrink tumors, boost immune response — Nature News — Engineered E. coli bacteria shrink tumors in mice by delivering anti-cancer drugs locally, while also boosting immune response.
• H. pylori linked to colorectal cancer via gut microbiome, immunity — Inside Precision Medicine — H. pylori is now linked to increased colorectal cancer risk through its impact on the gut microbiome and immune signaling, expanding its known pathology beyond ulcers.
• Leisure movement beats job-related activity for dementia risk — Longevity Technology — Leisure-time physical activity lowers dementia risk, but physically demanding jobs increase it, showing how you move matters more than just total movement for brain health.
• Nestle sells Nature's Bounty, Puritan's Pride brands for $1 billion — New Hope Network (Natural Products Expo) — Nestle sold its Nature's Bounty and Puritan's Pride supplement brands for $1 billion, signaling a consolidation and segmentation in the wellness supplement market.
• Clinical AI models outperform general LLMs for medical diagnosis — Nature Medicine RSS — Specialized clinical AI models still outperform general large language models for medical diagnosis, despite LLMs showing promise in generating differential diagnoses.
• Health insurers charging patients more via owned pharmacies — KFF Health News — Health insurers are directing patients to their own pharmacies, leading to higher out-of-pocket costs and limited drug access in the US, raising questions about vertical integration.
• Gene test spots seizure drug risk, averting severe skin reactions — Inside Precision Medicine — A new genetic test identifies a specific HLA variant (A*32:01) that can predict severe skin reactions to the anti-seizure drug lamotrigine, allowing for safer prescribing.

New this week in wellness goods

• Sky Labs' CART Ring Monitors Blood Pressure 24/7 — health monitoring — Sky Labs unveiled new clinical data at ESC 2026 for its CART ring, a blood pressure monitor designed for 24-hour tracking. The ring showed an 80% data rate in atrial fibrillation patients, even overnight. This means a continuous read on cardiovascular load, not just a snapshot.
• MyHeartCode uses epigenetics to map heart age — Global — Genetic LifeSpan launched MyHeartCode, a new service using epigenetic data to predict heart aging, aiming to provide a more nuanced risk assessment than traditional cholesterol numbers. This direct-to-consumer test promises to give people a clearer picture of their cardiovascular health beyond a single biomarker.
• Cumulus' EEG headset tracks brain health for ALS patients — north_america — Cumulus Neuroscience's NeuLogiq at-home EEG headset passed a usability test with ALS and FTD patients. This device helps track cognitive and mood changes, which traditional motor-focused ALS rating scales often miss.

Signal map

North America: 15 · Global: 13 · Europe: 8

What I'd watch next

Keep an eye on how US health insurers' vertical integration impacts patient cost and access. Also, watch for the outcomes of regulatory reviews on new 'longevity' drugs, as this will set precedents for a new category of treatments.

Where this fits at Kokorology

Understanding the nervous system's central role in health is key. The Nervous System Journal helps you track your own inputs and outputs, so you can see your patterns and adjust.